Claims for Patent: 9,655,907

Summary for Patent: 9,655,907

Title:	Topical formulations comprising a steroid
Abstract:	The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Inventor(s):	Ubaidulla; Udhumansha (Namakkal, IN), Kandavilli; Sateesh (Hyderabad, IN), Vairale; Ajay Sunil (Hyderabad, IN), Wayne; Jeffrey A. (Markham, CA), Nalamothu; Vijendra (Basking Ridge, NJ), Meghal; Mistry (Ahmedabad, IN), Pakunlu; Refika Isil (Highland Park, NJ)
Assignee:	Dr. Reddy's Laboratories Ltd. (Hyderabad, Telangana, IN)
Application Number:	15/226,684
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,655,907
Patent Claims:	1. A topical pharmaceutical composition, comprising: at least one steroid; an emulsifying agent; water; a water-immiscible substance; and a skin penetration enhancer selected from the group consisting of butanediol, polyethylene glycol monolaurate, diethylene glycol monoethyl ether, dimethylsulfoxide, decylmethylsulfoxide, lauric acid, oleic acid, valeric acid, isopropyl myristate, isopropyl palmitate, methyl propionate, ethyl oleate, and combinations thereof; wherein the composition is non-foaming, propylene glycol-free, alcohol-free, and propellant-free. 2. The composition according to claim 1, wherein the steroid is selected from the group consisting of alclometasone dipropionate, beclomethasone dipropionate, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, halobetasol propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone butyrate, mometasone furoate, triamcinolone acetonide, clocortolone pivalate, clobetasol propionate, desoximetasone, and fluticasone propionate. 3. The composition according to claim 1, wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof. 4. The composition according to claim 1, and further comprising a penetration enhancer. 5. The composition according to claim 4, wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight. 6. The composition according to claim 5, wherein the penetration enhancer is selected from the group consisting of a polyol and esters, ethers, sulfoxides, fatty acids, fatty acid esters, and any combination thereof. 7. The composition according to claim 1, wherein an emulsifying agent comprises a sorbitan fatty acid ester, a mixture of partial esters of sorbitol and its mono- and di-anhydhdes with fatty acids, a polyethylene glycol stearate, a glycol stearate, sodium lauryl sulphate, cetyl trialkyl ammonium bromide, a polyoxyethylene sorbitan fatty acid ester, or any combination thereof. 8. A sprayable topical pharmaceutical composition, comprising steroid, an emulsifying agent, a polymer, water, a water-immiscible substance, and a penetration enhancer; wherein said composition is substantially free of a propellant and propylene glycol; wherein the topical pharmaceutical is substantially non-foaming and substantially non-occlusive to the skin. 9. The composition according to claim 8, wherein the steroid is selected from the group comprising alclometasone dipropionate, beclomethasone dipropionate, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, halobetasol propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone butyrate, mometasone furoate, triamcinolone acetonide, clocortolone pivalate, clobetasol propionate, desoximetasone, and fluticasone propionate. 10. The composition according to claim 8 is substantially non-occlusive to the skin. 11. The composition according to claim 8 forms droplets upon application to the skin. 12. A sprayable topical pharmaceutical composition, comprising betamethasone compound, an emulsifying agent, a polymer, water, a water-immiscible substance, and a penetration enhancer; wherein said composition is substantially free of a propellant and propylene glycol; wherein the topical pharmaceutical composition is substantially non-foaming. 13. The composition according to claim 12 is substantially non-occlusive to the skin. 14. The composition according to claim 12 forms droplets upon application to the skin. 15. The composition according to claim 12, wherein the betamethasone compound is in amounts equivalent to about 0.025 to about 0.1 percent by weight of betamethasone base. 16. The composition according to claim 12, wherein the betamethasone compound is betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate. 17. The composition according to claim 12, comprising a polymer selected from the group consisting of a cellulose, a gum, an alginate, and a phthalate. 18. The composition according to claim 12, comprising a emulsifying agent selected from the group comprising of sorbitan stearate. 19. The composition according to claim 12, wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof. 20. The composition of claim 12, wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight. 21. The composition according to claim 12, wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise. 22. A method of treating a skin condition comprising administering pharmaceutically effective amount of the composition according to claim 1 to a subject in need thereof, wherein the condition is selected from one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reactions, and other associated diseases or disorders.